Placebo pMDI
Placebo pMDI is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
0
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers
Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
Clinical Trials (5)
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers
Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5